SC 57461Alternative Names: SC 57461A
Latest Information Update: 12 Sep 2006
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammatory bowel diseases